In people with no history of CV disease, N-terminal pro-brain natriuretic peptide (NT-proBNP) levels can predict a higher risk of developing CV disease across various blood pressure and pulse pressure ...

Jan. 6, 2006 — The US Food and Drug Administration (FDA) approved in 2005 a rapid point-of-care test for adenovirus in tear fluid as an aid in the differential diagnosis of acute conjunctivitis; a new ...

San Francisco, CA - Measurement of serum amino terminal fragment of prohormone brain-type natriuretic peptide (NT-proBNP) can add useful information to the standard risk assessment of people with ...

Run on the highly portable LumiraDx Platform, the LumiraDx NT-proBNP test is a quantitative, fingerstick blood assay designed for near-patient testing with lab-comparable results in 12 minutes. It is ...

A simple blood test for the protein NT-proBNP accurately predicts the risk of heart attack, heart failure, stroke and death in patients with known cardiovascular disease, according to a study led by a ...

The diagnostic potential of N-terminal pro-B-type natriuretic peptide (NT-proBNP) testing in patients with suspected heart failure (HF) has been demonstrated, but whether this test reduces costs and ...

The LumiraDx NT-proBNP and the LumiraDx D-Dimer tests are currently the only quantitative direct fingerstick assays produced for each test. Run on the highly portable LumiraDx Platform, they are ...

In search of the Point-of-Care NT-proBNP Test in the USA? Reach out to Response Biomedical today for prompt assistance. Contact us now! VANCOUVER, WASHINGTON, USA, May 24, 2023/einpresswire.com / -- ...

Q: Rambo, my 2-year-old cat, was breathing fast during his annual wellness exam. His veterinarian said his rapid breathing could be due to stress, heart disease or a respiratory condition such as ...

LONDON, June 2, 2022 /PRNewswire/ -- LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care diagnostics company, today announced it has expanded its cardiovascular offering with a CE Mark ...